Regeneron Sees FY23 Adj. R&D $3.825B-$3.925B
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has projected its adjusted R&D expenses for the fiscal year 2023 to be between $3.825 billion and $3.925 billion.
August 04, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron's projected increase in R&D expenses for FY23 could potentially impact its profitability and stock performance.
Increased R&D expenses can lead to a decrease in net income, which could negatively impact the company's stock price. However, it could also lead to the development of new products, which could positively impact the company's future profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100